/PFSA
PFSA Stock - Profusa, Inc. Common Stock
Healthcare|Medical - Equipment & ServicesNASDAQ
$0.12+4.35%
+$0.00 (+4.35%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PFSA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.12 – $0.12
TARGET (TP)$0.14
STOP LOSS$0.11
RISK/REWARD1:3.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.20
52W High$5.50
52W Low$0.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-4,500,000 | $-6,070,000 | $-11,140,000 | $-11,690,000 |
| Net Income | $-9,230,000 | $-10,281,000 | $-20,217,000 | $-10,310,000 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-0.28 | $-0.31 | $-0.62 | $-0.31 |
Company Overview
A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PFSABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.70
Q4 2025
EPS Surprise History
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 19, 2025 | — | $-0.70 | — | — |
Latest News
PFSA stock has given up its prior gain. Profusa shares were trading higher after the company reported late-breaking data showing its Lumee oxygen monitoring system met primary endpoints in a peripheral artery disease study.
➖ NeutralBenzinga•Dec 15, 2025, 02:59 PM
Profusa shares are trading higher after the company reported late-breaking data showing its Lumee oxygen monitoring system met primary endpoints in a peripheral artery disease study.
📈 PositiveBenzinga•Dec 15, 2025, 12:45 PM
Profusa Presents Late Breaking Data Showing Lumee Oxygen Monitoring Meets Primary End Points In Peripheral Artery Disease Study
📈 PositiveBenzinga•Dec 15, 2025, 12:37 PM
Profusa Abstract Accepted For LINC 2026; Presentation To Highlight Tissue Oxygen Monitoring Insights In PAD Pilot Study
📈 PositiveBenzinga•Dec 11, 2025, 01:37 PM
Profusa To Present Abstract Titled 'Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease ' At Paris Vascular Insights 2025
➖ NeutralBenzinga•Nov 24, 2025, 01:16 PM
Profusa CEO Says 'Co To Capitalize On The Near-Term European And U.S. Lumee Oxygen Opportunity To Deliver 2026 Potential Revenue Of $500K To $2M And $9M To $13M Potential Revenue In 2027
📈 PositiveBenzinga•Nov 19, 2025, 10:56 PM
Profusa outlines revenue plan, targets EU commercial launch of Lumee in early Q2 2026
📈 PositiveSeeking Alpha•Oct 30, 2025, 11:51 AM
Profusa Targets $250M Revenue By 2030 Driven By Sequential Launches Of Lumee Oxygen And Glucose Monitoring Platforms
📈 PositiveBenzinga•Oct 30, 2025, 11:44 AM
Profusa Signs LOI To Establish Logistics And Commercialization Footprint With Angiopro GmbH For Lumee Oxygen Platform In Europe
📈 PositiveBenzinga•Oct 22, 2025, 01:30 PM
Profusa To Expand Commercial Footprint For Lumee Oxygen Platform In Europe Under Signed Letter Of Intent With Angiopro GmbH
📈 PositiveBenzinga•Oct 15, 2025, 12:44 PM
Profusa Files Prospectus Relates To Resale, From Time To Time By Selling Stockholders Of Up To 42.6M Shares
➖ NeutralBenzinga•Oct 9, 2025, 09:29 PM
Profusa Invests Additional $1M In Bitcoin As Part Of Digital Treasury Strategy
📈 PositiveBenzinga•Oct 7, 2025, 12:16 PM•Also: , ,
Profusa shares are trading higher after the company announced the adoption of NVIDIA technology to power an AI-driven insight portal for continuous biochemistry monitoring.
📈 PositiveBenzinga•Sep 11, 2025, 12:34 PM•Also:
Profusa Adopts NVIDIA-Powered Technology For AI-Driven Insight Portal For Continuous Biochemistry Monitoring
📈 PositiveBenzinga•Sep 11, 2025, 12:33 PM•Also:
Profusa Partners With Prof. Dr. Marianne Brodmann For Clinical Adoption And Integration Of Lumee Oxygen Platform
📈 PositiveBenzinga•Aug 27, 2025, 12:47 PM
Profusa Appoints Fred Knechtel As CFO
➖ NeutralBenzinga•Aug 19, 2025, 12:19 PM
Frequently Asked Questions about PFSA
What is PFSA's current stock price?
Profusa, Inc. Common Stock (PFSA) is currently trading at $0.12 per share. The stock has moved +4.35% today.
What is the analyst price target for PFSA?
No analyst price targets are currently available for this stock.
What sector is Profusa, Inc. Common Stock in?
Profusa, Inc. Common Stock operates in the Healthcare sector, specifically within the Medical - Equipment & Services industry. The company is traded on the NASDAQ exchange.
What is PFSA's market cap?
Profusa, Inc. Common Stock has a market capitalization of $0.00 billion, making it a small-cap company.
Does PFSA pay dividends?
No, Profusa, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
ADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
BFRI
Biofrontera Inc.
$0.77
Mkt Cap: $0.0B
CHEK
Check-Cap Ltd.
$1.61
Mkt Cap: $0.0B
GBS
GBS Inc.
$0.47
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
LUCY
Innovative Eyewear, Inc.
$1.38
Mkt Cap: $0.0B
SBFM
Sunshine Biopharma, Inc.
$1.39
Mkt Cap: $0.0B
Explore stocks similar to PFSA for comparison